Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Kukjeon Pharmaceutical Co Ltd (307750)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5,650 +60    +1.07%
02:30:30 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7307750000 
  • Volume: 63,206
  • Bid/Ask: 5,640 / 5,650
  • Day's Range: 5,580 - 5,660
Kukjeon Pharmaceutical 5,650 +60 +1.07%

307750 Balance Sheet

 
Featured here, the Balance Sheet for Kukjeon Pharmaceutical Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 123991.8 122202.28 123116.65 136492.74
Cash and Short Term Investments 64832.52 56974.24 61500.43 76513.94
Cash - - - -
Cash & Equivalents 10992.4 4943.26 12735.86 19581.77
Short Term Investments 15000 20000 40000 55000
Total Receivables, Net 29065.21 34062.91 31509.4 31276.71
Accounts Receivables - Trade, Net 26849.93 30668.86 28204.16 28184.03
Total Inventory 27563.4 28131.29 28790.12 26343.8
Prepaid Expenses 494.91 389.52 481.86 357.28
Other Current Assets, Total 2035.75 2644.33 834.84 2001
Total Assets 225102.49 218993.68 209661.53 207772.17
Property/Plant/Equipment, Total - Net 86060.38 83537.09 74306.94 58922.85
Property/Plant/Equipment, Total - Gross 97810.53 94265.11 84096.58 68242.45
Accumulated Depreciation, Total -11750.15 -10728.02 -9789.63 -9319.6
Goodwill, Net 420.39 420.39 420.39 420.39
Intangibles, Net 971 998.1 1025.21 1050.33
Long Term Investments 4364.16 4542.46 2548.71 2921.37
Note Receivable - Long Term 1964.4 2643.34 2629.1 2475.68
Other Long Term Assets, Total 7090.43 6914.64 8023.63 7674.49
Other Assets, Total 56829.29 49873.11 47776.27 54907.27
Total Current Liabilities 99822.58 105161.25 81613.63 77894.92
Accounts Payable 11692.68 13846.77 14597.29 13806.5
Payable/Accrued - - - -
Accrued Expenses 289.73 309.92 208.92 201.6
Notes Payable/Short Term Debt 15223.99 49309.3 36962.29 38044.67
Current Port. of LT Debt/Capital Leases 37038.58 1495.14 1511.84 1430.37
Other Current liabilities, Total 35577.6 40200.12 28333.28 24411.78
Total Liabilities 127646.22 125030.21 114406.3 110839.5
Total Long Term Debt 26517.42 18595.47 25211 25100.79
Long Term Debt 26183.28 18324.35 24999.24 24881.67
Capital Lease Obligations 334.14 271.12 211.75 219.12
Deferred Income Tax 10.45 52.25 663.76 2007.29
Minority Interest 1034.74 672.47 679.22 679.7
Other Liabilities, Total -14962.95 -48760.53 -30723.6 -38387.87
Total Equity 97456.27 93963.47 95255.23 96932.67
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 4906.93 4906.93 4906.93 4906.93
Additional Paid-In Capital 62386.36 62386.36 62386.36 62386.36
Retained Earnings (Accumulated Deficit) 29129.41 25998.87 27283.88 28960.85
Treasury Stock - Common -1.16 -1.16 -1.16 -1.16
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 1034.74 672.47 679.22 679.7
Total Liabilities & Shareholders' Equity 225102.49 218993.68 209661.53 207772.17
Total Common Shares Outstanding 49.07 49.07 49.07 49.07
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

307750 Comments

Write your thoughts about Kukjeon Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email